Recent trends in the treatment of unresectable stage III non-small-cell lung cancer

Go Makimoto, Katsuyuki Hotta, Katsuyuki Kiura

Research output: Contribution to journalReview articlepeer-review

7 Citations (Scopus)


Approximately 20–25% of non-small-cell lung cancer (NSCLC) is diagnosed when the disease has progressed to clinical stage III. At this stage, and even if the cancer is considered unresectable, the treatment strategy should aim to achieve a cure. At the time of the initial diagnosis, it is necessary for medical oncologists to devise the best treatment strategy for each patient by composing a multidisciplinary treatment team including thoracic surgeons and radiation oncologists. In this review, we summarize prior pivotal clinical trials in unresectable clinical stage III NSCLC. Furthermore, we review very recent clinical trials evaluating the efficacy of immune checkpoint inhibitors in the treatment of NSCLC.

Original languageEnglish
Pages (from-to)330-336
Number of pages7
JournalRespiratory Investigation
Issue number4
Publication statusPublished - Jul 2019


  • Chemoradiotherapy
  • Durvalumab
  • Immune checkpoint inhibitor
  • Lung cancer
  • Stage III

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'Recent trends in the treatment of unresectable stage III non-small-cell lung cancer'. Together they form a unique fingerprint.

Cite this